ACTH fragment is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-03-18. Where a claim depends on a specific study, the study is described rather than over-claimed.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It is described in the literature as an analogue of the ACTH(4–10) fragment, a short N-terminal portion of adrenocorticotropic hormone that retains some neurotropic activity without the full hormonal effects of the parent peptide. The molecule carries a methionine residue at the N-terminus and two proline residues near the C-terminus, features that shape both its interactions with receptor systems and its chemical stability. The free peptide corresponds to the formula C37H51N9O10S and a molecular mass near 813.9 Da.
The compound was developed in the 1980s at the Institute of Molecular Genetics in Moscow, where it emerged from research on short ACTH fragments and their effects on the central nervous system. Russian pharmaceutical listings describe it as a nootropic and neuroprotective agent, most often formulated as nasal drops. It is not a marketed medicine in the United States or the European Union, and no pharmacopoeial monograph covers it. Consequently, most published clinical experience with the substance originates from a small number of research centres, mainly in Russia and neighbouring countries.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its design combines the ACTH(4-7) core fragment with a C-terminal Pro-Gly-Pro extension, a modification intended to improve stability and prolong activity. The molecule is hydrophilic, carries no lipid chains or glycosylation, and has a theoretical mass just over 810 daltons in its free form. All seven residues are proteinogenic amino acids, so no non-natural building blocks appear in the backbone. A free N-terminal methionine and C-terminal proline define the unmodified parent peptide.
The compound was developed during the 1980s at the Institute of Molecular Genetics in Moscow as part of research on fragments of adrenocorticotropic hormone. Early work examined short ACTH-derived sequences that retained neurotrophic effects while lacking the endocrine activity of the full hormone. Semax entered clinical use in Russia during the 1990s, where it received registration for several neurological indications. Outside that region it remained primarily a laboratory research material rather than an approved therapeutic. English-language literature on it grew more slowly and frequently cited the original Russian studies.
Terminology around the compound varies by source. It appears in catalogues and papers as Semax, as the heptapeptide ACTH(4-7)-Pro-Gly-Pro, and under various alphanumeric laboratory codes used by individual suppliers. These names refer to the same sequence but may imply different salt forms, purity grades, or counter-ions. Peptide databases usually list the free base mass, while product descriptions sometimes report acetate or trifluoroacetate salts with a different formula weight. Because naming conventions for research peptides are not standardised across vendors, checking the declared sequence and measured mass is more reliable than relying on a trade name alone.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C37H51N9O10S | Free acid form of the heptapeptide; depends on terminal groups |
| Molecular mass | About 813.9 g/mol | Average mass used for mass spectrometry confirmation |
| Appearance | White to off-white solid | Supplied as a lyophilised powder; hygroscopic |
| Solubility class | Freely soluble in aqueous media | Water, saline, and phosphate buffers; limited organic solubility |
| Typical storage temperature | -20 degrees Celsius | Long term and dry; short working periods may use 2 to 8 degrees Celsius |
Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. It was developed as a fragment analog of adrenocorticotropic hormone, modeled specifically on the ACTH(4-10) region. The first four residues reproduce that fragment, while a Pro-Gly-Pro tripeptide is appended at the C-terminus. Work on the compound originated in Russia, where it entered clinical use as an intranasal preparation. Its sequence places it among short regulatory peptides studied for effects on the central nervous system rather than on the adrenal axis.
The C-terminal Pro-Gly-Pro extension is not incidental. Proline-rich tails are known to resist several common peptidases, and the published literature attributes the longer half-life of Semax, relative to unmodified ACTH fragments, to this feature. The modification also removes the melanocyte-stimulating and corticosteroidogenic activity that characterizes longer ACTH-derived sequences. Because the molecule is small and hydrophilic, it is typically formulated as an aqueous solution for intranasal or parenteral delivery. Acetylation or amidation at the termini appears in closely related research peptides and shifts the mass by a fixed increment.
Semax is a synthetic heptapeptide developed in the Soviet Union during the 1980s by researchers at the Institute of Molecular Genetics in Moscow. It was designed as a truncated analog of adrenocorticotropic hormone, retaining only the fragment spanning residues four through ten. Investigators sought a peptide that would preserve the cognitive effects associated with ACTH while eliminating the hormonal stimulation of the adrenal cortex. The compound entered clinical use in Russia during the following decade.
Russian regulatory authorities approved the peptide for nasal administration, and it remains listed in the national pharmacopoeia under several trade names. Documented indications include acute ischemic stroke, transient ischemic attacks, traumatic brain injury, and certain ophthalmological and neurological conditions. Physicians also prescribe it for cognitive complaints in older patients, although the evidence base for that use is thinner. Outside Russia and a few neighboring states, the substance is not an approved medicine and is sold instead as a research chemical.
Development of the compound took place in the Soviet Union during the 1980s, largely through peptide research groups affiliated with the Shemyakin-Ovchinnikov Institute and Moscow State University. Investigators screened fragments of adrenocorticotropic hormone for activity on the central nervous system while attempting to separate cognitive effects from hormonal ones. The shortened sequence was selected because it retained behavioral activity in animal models without stimulating corticosteroid release. Early publications described the molecule as an ACTH(4-10) analog.
Published research on this peptide originates mainly from Russian laboratories, and the wider international literature is comparatively thin. Studies have used rodent models of stroke, hypoxia, and memory tasks, with a smaller number of human trials reported. Reported outcomes include changes in attention and memory measures, along with effects on neurotrophic factor expression in some experiments. Small sample sizes, inconsistent dosing protocols, and limited independent replication are widely noted limitations, so the strength of the clinical evidence remains an open question.
Semax is a synthetic seven-amino-acid peptide whose sequence extends the ACTH(4-10) fragment with a C-terminal proline-glycine-proline tripeptide. The commonly cited sequence is Met-Glu-His-Phe-Pro-Gly-Pro, giving a molecular formula near C37H51N9O10S and a molecular weight close to 813.9 g/mol. It belongs to the broader class of synthetic ACTH fragments studied for central nervous system effects rather than for adrenal steroid stimulation. In practice the material appears as a lyophilized white powder for laboratory work or as a dilute saline solution in clinical settings.
Development is attributed to researchers at the Institute of Molecular Genetics in Moscow during the early 1980s, building on earlier Soviet work with ACTH fragments. Russian regulatory approval followed for intranasal use, and the compound has remained commercially available there for decades. Most published human data originate from Russian and, later, some Eastern European clinical reports, which are not always accessible in English translation. Outside that region the material is generally handled as a research chemical rather than a licensed medicine.
Regulatory status differs sharply between jurisdictions. In Russia the peptide is registered as a prescription nasal preparation, while agencies such as the United States Food and Drug Administration have not approved it for any indication. Products sold elsewhere are typically labeled for laboratory research only, and such labels shift responsibility for safe handling to the purchaser. Because the same name covers pharmaceutical-grade nasal drops and bulk research powder, identity and purity documentation becomes the main practical concern when comparing sources.
=== 6th Congress – CLP disbands (1993) === On January 31, 1993, at the Sixth Congress, the CLP voted unanimously to disband. This proposal was thoroughly discussed leading up to the 6th Congress. While many members initially had serious questions about the move to disband, they were eventually won over. One of the main arguments was that the CLP had failed to recruit new people and grow. Members believed that the organizational form of the CLP was not conducive to the further development of the revolutionary process. The "Call for the 6th Party Congress” (Rally, Comrades! Nov. 1992) raised the question, "What is the proper organizational form for revolutionaries in this quantitative stage of the revolution?” The Call states, "… this is not a time of preparation for the seizure of power. This is the moment to organize and politicize the social revolution. This is a time to struggle for the unity and political clarity of the millions who are in the diverse and daily struggle for jobs, health care and the other necessities of their lives.
In post-WW1 Hungary, arsenic extracted by boiling fly paper was used in an estimated 300 murders by the Angel Makers of Nagyrév. In imperial China, arsenic trioxide and sulfides were used in murder, as well as for capital punishment for members of the royal family or aristocracy. Forensic studies have determined that the Guangxu Emperor (d. 1908) was murdered by arsenic, most likely ordered by the Empress Dowager Cixi or Generalissimo Yuan Shikai. Likewise, in ancient Korea, and particularly in the Joseon Dynasty, arsenic-sulfur compounds had been used as a major ingredient of sayak (사약; 賜藥), which was a poison cocktail used in capital punishment of high-profile political figures and members of the royal family. Due to social and political prominence of the condemned, many of these events were well-documented, often in the Annals of Joseon Dynasty; they are sometimes portrayed in historical television miniseries because of their dramatic nature. Arsenic-contaminated beer poisoned over 6,000 people in the Manchester area of England in 1900, and is thought to have killed at least 70 victims. Mass arsenic poisoning due to naturally occurring arsenic in drinking water was first noted by Dr. Abel Ayerza in Córdoba, Argentina in a paper published in 1918. One of the worst incidents of arsenic poisoning via well water occurred in Bangladesh with the mass installation of tube wells following Bangladesh's independence in 1971. The World Health Organization called this the "largest mass poisoning of a population in history" and was recognized as a major public health concern.
An analysis of events in the US FDA Adverse Event Reporting System suggests an association between several GLP-1 agonists (including semaglutide) and cutaneous reactions, such as dermal hypersensitivity reactions, eosinophilic panniculitis, bullous pemphigoid, and morbilliform drug eruptions. In August 2026, a post hoc analysis of the SELECT phase 3 trial involving adults aged 65 and older without diabetes revealed that 104 weeks of semaglutide treatment slowed the progression of a validated 25-protein blood signature (Dementia SomaSignal Test) predicting long-term all-cause dementia risk. Participants receiving semaglutide experienced a 26% lower predicted 5-year dementia risk compared to placebo, with the majority of the protective association persisting independent of weight loss alone.
Sources: en.wikipedia.org
For non-small cell lung cancer, pembrolizumab is used in combination with chemotherapy (for all PD-L1, a PD-1 receptor ligand, levels) or by itself as a first-line treatment if the cancer expresses (≥ 1%) PD-L1 and the cancer has no mutations in EGFR or in ALK; if chemotherapy has already been administered, then pembrolizumab can be used as a second-line treatment, but if the cancer has EGFR or ALK mutations, agents targeting those mutations should be used first. Assessment of PD-L1 expression must be conducted with a validated and approved companion diagnostic.
β-Hydroxy β-methylglutaryl-CoA (HMG-CoA), also known as 3-hydroxy-3-methylglutaryl coenzyme A, is an intermediate in the mevalonate and ketogenesis pathways. It is formed from acetyl CoA and acetoacetyl CoA by HMG-CoA synthase. The research of Minor J. Coon and Bimal Kumar Bachhawat in the 1950s at University of Illinois led to its discovery. HMG-CoA is a metabolic intermediate in the metabolism of the branched-chain amino acids, which include leucine, isoleucine, and valine. Its immediate precursors are β-methylglutaconyl-CoA (MG-CoA) and β-hydroxy β-methylbutyryl-CoA (HMB-CoA). HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonic acid, a necessary step in the biosynthesis of cholesterol.
In principle, mandating countries were only supposed to hold these former colonies "in trust" for their inhabitants, until they were sufficiently prepared for their own self-determination. Under these terms, Japan, Australia, and New Zealand were granted the German Pacific islands, and the Union of South Africa received South West Africa. It soon became apparent the South African government had interpreted the mandate as a veiled annexation. In September 1922, South African Prime Minister Jan Smuts testified before the League of Nations Mandate Commission that South West Africa was being fully incorporated into the Union and should be regarded, for all practical purposes, as a fifth province of South Africa. According to Smuts, this constituted "annexation in all but in name". Throughout the 1920s and 1930s, the League of Nations complained that of all the mandatory powers South Africa was the most delinquent with regards to observing the terms of its mandate. The Mandate Commission vetoed a number of ambitious South African policy decisions, such as proposals to nationalise South West African railways or alter the preexisting borders. Sharp criticism was also leveled at South Africa's disproportionate spending on the local white population, which the former defended as obligatory since white South West Africans were taxed the heaviest.
Sources: en.wikipedia.org
Sanders expresses her disappointment in the fact that even if they are able to find a diagnosis or treatment for his illness, he may not be able to recover all the memories he has already lost. From the hundreds of responses Dr. Sanders highlighted 2 very interesting possibilities one caused by a virus and the other caused by an autoimmune disorder. The first possibility is Progressive Multifocal Leukoencephalopathy that is caused by a virus and destroys the brain's ability to translate information. The second possibility is a very rare autoimmune disease by the name of Neuro-Behcet’s that causes inflammation and ulceration in different types of the body. Neither of these diagnoses seemed to fit Willie exactly because of key features such as Willie’s very strong immune system and the fact that he had no response to steroids. Due to Willie’s background in the Army, the suggestion of the Gulf War Illness was brought up. When Dr. Sanders brought this idea to another physician for a second diagnosis, they highlighted key similarities between Willie's condition and the Gulf War Illness despite his being much more severe. The idea of the Gulf War Illness was tossed around as a possibility and brought up to many physicians for second opinions, each one highlighting his symptoms are much more severe, and suggesting the possibility of testing for further clarity. To better understand the chances of Willie having the Gulf War Illness, they need to know if he was exposed to the toxins present during the Gulf War.
The Centre Party (German: Zentrum, Z), officially the German Centre Party (German: Deutsche Zentrumspartei, DZP) and also known in English as the Catholic Centre Party, is a Christian democratic political party in Germany. It was most influential in the German Empire and Weimar Republic. Formed in 1870, it successfully battled the Kulturkampf waged by Chancellor Otto von Bismarck against the Catholic Church. It soon won a quarter of the seats in the Reichstag, and its middle position on most issues allowed it to play a decisive role in the formation of majorities. The party name Zentrum (Centre) originally came from the fact that Catholic representatives would take up the middle section of seats in parliament between the social democrats and the conservatives. For most of the Weimar Republic, the Centre Party was the third-largest party in the Reichstag and a bulwark of the Republic, participating in all governments until 1932. Following Adolf Hitler's rise to power in early 1933, the Centre Party was among the parties who voted for the Enabling Act, which granted legislative powers to Hitler's government. Nevertheless, the party was pressured into dissolving itself on 5 July, as the Nazi Party became the only legally permitted party in the country shortly thereafter. After World War II, the party was reconstituted, but could not rise again to its former importance, as most of its members joined the new interdenominational Christian Democratic Union (CDU) and, in Bavaria, the Christian Social Union (CSU).
=== Cell wall === Like other Gram-positive microbes, S. haemolyticus has a thick, rather homogenous, cell wall (60-80 nm) composed of peptidoglycan, teichoic acid, and protein. Peptidoglycan of group A3 (with L-lysine as the diamino acid in position 3 of the peptide subunit and a glycine-rich interpeptide bridge) is a characteristic feature of this microbe, and the two predominant cross-bridges are COOH-Gly-Gly-Ser-Gly-Gly-NH2 and COOH-Ala-Gly-Ser-Gly-Gly-NH2. Alterations of these cross-bridges are implicated in glycopeptide resistance. S. haemolyticus teichoic acids are water-soluble polymers with repeating phosphodiester groups covalently linked to peptidoglycan. Peptidoglycan type L-Lys-Gly 3.5-4.0, L-Ser0.9-1.5 Teichoic acid contains both glycerol and N-acetylglucosamine. The major cell wall fatty acids are CBr-15, CBr-17, C18, and C20.
Sources: en.wikipedia.org
It is described as a synthetic analogue of the ACTH(4–10) fragment, a short segment of adrenocorticotropic hormone. Its sequence differs from that fragment and includes two proline residues, which influence stability and behaviour in solution.
It appears in Russian pharmaceutical listings as a nasal formulation, but it is not an authorised medicine in the United States or the European Union. Outside those markets it is normally encountered as a research chemical rather than a prescription product.
Laboratory and animal work points to melanocortin signalling and changes in neurotrophic factor levels, especially brain-derived neurotrophic factor. The exact receptor targets and the degree to which these findings transfer to humans are still unresolved.
It is a synthetic seven-amino-acid peptide built from the ACTH(4-7) sequence plus a Pro-Gly-Pro tail. It belongs to the family of short ACTH fragments studied for nervous-system effects. Its backbone contains only standard amino acids.